At week 24, there was a decrease of VL levels to G400 copies/ml in 82 to 100% of cohort II and in 85 to 98% in cohort (I + II). VL G50 copies and changes from baseline CD4+ T count were comparable for these groups. The mean increase in CD4+ T-cells was comparable in the efavienz and raltegravir groups at weeks 24 and 48. Of note, patients receiving raltegravir at any dose had a greater likelihood of achieving an HIV-1 RNA level G50 copies/ml at weeks 2, 4, and 8 than patients receiving efavirenz (pG0.05). These differences diminished over time, and by week 24, all groups had similar proportions of patients with suppressed VLs. Virologic failure was low (3%) and comparable in the efavirenz and raltegravir groups. A novel resistance mutation, a N155H amino acid substitution in the integrase region, was detected in the raltegravir groups. The incidence of serious adverse events was similar in the efavirenz and raltegravir groups, but drug-related adverse events were more frequently seen with the efavirenz combination regimen than the raltegravir one (p=0.04 for 100-, 400-, and 600-mg groups and p=0.07 for the 200-mg group).
COMMENTARY
Over the last two decades, the combined efforts of basic and clinical scientists, advocacy groups, science administrators, venture capitalists, politicians, and patient volunteers have produced more than 20 drugs capable of controlling HIV-1 infection. Thus far, these drugs have targeted only the reverse transcription, protein cleavage, and fusion inhibition of the viral production cycle. Due to their potent, but as yet incomplete, inhibition of viral reproduction, drugs with less toxicity and better efficacy are still needed. Raltegravir represents a new class of drug (integrase inhibitors) that may considerably improve our current antiretroviral armamentarium.
The worldwide HIV-1 incidence continues to grow; likewise, the attributable mortality and morbidity increase despite the availability of HIV drugs and advances made in understanding the disease and the treatment management. Current medication using combinations of therapy [nonnucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), and fusion inhibitors] face great challenges due to the toxicity and resistance related to the long-term use of these drugs. This situation creates an urgent need for new classes of drugs. Raltegravir has been tested through studies of safety, tolerability, and pharmacokinetics after both single and multiple doses over prolonged periods up to 48 weeks. It has demonstrable efficacy both in vivo and clinically. Although satisfactory responses have been observed when raltegravir is used in combination with tenofovir and lamivudine, other studies are still needed to evaluate raltegravir when combined with the other NRTIs and with the other drug classes.
Other new additions to our therapeutic armamentarium against HIV infection, the CCR5 inhibitors, are soon to become available. Available data cannot yet tell us how valuable these new drugs will be. What is very intriguing and exciting about raltegravir, however, is the more rapid HIV clearance that is seen compared to current agents. The significance of this rapid clearance and the apparent safety profile of raltegravir suggests that this drug will be adopted quickly when it becomes widely available. 
SUMMARY
This retrospective population based-study from January 1, 1995 , to December 31, 2001 , evaluated the impact of antiretroviral therapy (ART) on the incidence of tuberculosis (TB) in the Brazilian public sector. Four hundred and sixty-three subjects met the study criteria, which excluded patients under 18 years of age, pregnant individuals, patients who were wards of the state, or patients who had a diagnosis of TB within 30 days of the recorded initial facility visit. Of those 463 subjects, 76 were ART-naïve, 81 received nonhighly active ART (any single antiretroviral drug or combination not defined as highly active), and 306 took HAART, defined as a combination of 2 nucleoside reverse transcriptase inhibitors (NRTI) + 1 protease inhibitor (PI), or 2 NRTI + 1 nonnucleoside reverse transcriptase inhibitor (NNRTI), or 1 NRTI + 1 NNRTI + 1 PI.
Of 379 patients records, 229 had a baseline viral load (VL) ≥10,000 copies/ml, 116 presented with a VL ≥100,000 copies/ml; 223/271 (82%) of persons who had a CD4+ T lymphocyte count recorded had a baseline count G200 cells/mm 3 . During the study period, 39 persons were diagnosed with TB; 18 (46%) occurred in ART-naïve patients. A higher proportion of patients with TB had baseline CD4+ T counts G200 cells/mm 3 compared with patients without TB (57 vs. 37%, p=0.01). Persons with a baseline CD4+ T count G200 cells/mm 3 had more than twice the incidence of TB than those with a baseline CD4+ T count 9200 cells/mm 3 [hazard ratio (HR), 2.3; 95% confidence interval (CI) (1.2, 4.4)]. ART-naïve patients had a significantly higher incidence of TB than those receiving any ART [HR, 5.0; 95% CI, (3.3, 10.0); pG0.01). Compared with ART-naïve subjects, significant protective effects against the incidence of TB were observed for both non-HAART ART [HR 0.4; 95% CI (0.2, 0.9), p=0.03] and HAART [HR 0.1; 95% CI (0.1, 0.2), pG0.001].
COMMENTARY
The incidence of tuberculosis (TB) has seen a dramatic increase due to the HIV pandemic. The use of HAART has been shown to have a major impact on the reduction in the risk of TB of the order of 70 to 90% in the HIV population in countries with both low and high prevalences of TB. This study nicely demonstrates how control of HIV in the public sector in Brazil can have a major impact on the incidence of TB in the HIV-infected populace, a major source of new cases of TB worldwide. However, more information is needed to clarify whether the long-term use of HAART (with VL suppression) may lead to a full restoration of immune system capacity with normalization of cell phenotype and function, as well as quantitative restoration of immune cells. It has been shown that a low CD4+T cell level is an important risk factor for the development of TB, but it remains to be determined what the optimal timing for initiation of HAART should be in the context of coinfection with TB and HIV.
TB control is a double challenge in the HIV-infected population; strategies for reducing the overall incidence of TB in the population such as with directly observed treatment should be improved and reinforced. Additionally, strategies for prompt diagnosis of both TB and HIV and effective treatment management of TB and HIV are required to control the dual epidemic. Failure to address the critical epidemic of TB and HIV coinfection has led to and will continue to lead to the development of the multidrug-resistant (MDR) and extreme-drug-resistant (XDR) TB, strains of TB that are highly lethal and extraordinarily difficult to treat. HIV and TB coinfected patient treatment is one more challenge due to the pill burden (adherence problem), drug interactions, and toxicity. It is incumbent on all persons concerned about public health to engage national and international institutions and governments to devote time and resources to address the dual epidemic of TB and HIV. It has been readily demonstrated that the epidemics can be controlled if the means to do so are made available. 
SUMMARY
The dynamics of changes in CD4+ T cell counts in HIV-1-infected patients using combination antiretroviral therapy (cART) have not been fully described. This prospective European study aims to describe the relationship between duration of treatment, CD4+ T cell count at the start of cART, current CD4+ T cell count, and CD4+ T cell count increase in ARV-naïve patients with viral load (VL) G50 copies/ml. There were 1,835 patients eligible for the study who had a CD4+ T cell count measured in the 6 months before starting cART. Baseline HIV VL was taken as the mean of the first two consecutive HIV VL G50 copies/ml after starting cART. CD4+ T cell counts were measured at the same time as VL measurements. The change in CD4+ T cell count occurring between each pair of consecutive VL counts of G50 copies/ml was calculated and standardized for the time between measurements to give the yearly change in CD4+ T cell count. Pairs of VL measurements were excluded if any change (start or stop) in antiretrovirals had been made between the measurements. The cART used were two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) plus a single protease inhibitor (PI), ritonavir boosted protease inhibitor (bPI), a nonnucleoside reverse transcriptase inhibitor (NNRTI), or abacavir.
Seven-hundred and forty-two (40.4%) patients had a CD4+ T cell count of 350 cells per microliter or less at baseline; the median CD4+ T cell count was 404 cells per microliter. The median time between VL measurement was 3 months, and a median of six pairs of VL G50 copies/ml per patient were included in the analysis. Of the 1,353 pairs of VL G50 copies/ml with concurrent CD4+ T cell counts ≤200 cells/μl, the mean rate of increase was 74 CD4+ T cells/μl per year (95% CI 58-91). The only group that did not have a significant increase in CD4+ T cells was the group of patients with counts 9700 cells/μl, where the mean yearly change in CD4+ T cell count was only 18 cells/μl. In patients with current CD4+ T cell counts G700 cells/μl, there was a 40-to 60-CD4+-T-cells/μl rise per year. The greatest increase in CD4+ T cell count was approximately 100 cells/μl, and this was seen in the year after starting cART, irrespective of CD4+ T cell count at the initiation of cART. Lower but significant increases in CD4+ T cell counts (about 50 cells/μl/year) were seen for up to 5 years after starting cART in patients with baseline CD4+ T cell count G500 cells/μl. The only group without significant change in yearly CD4+ T cell count was patients who took cART for more than 5 years with a current CD4+ T cell count more than 500 cells/μl, with a median CD4+ T cell count of 774 cells/μl (95% CI 764, 783).
COMMENTARY
The use of cART contributes highly to a remarkable suppression of HIV plasma VL, most often to G50 copies/ml, and is associated with substantial immune restoration.
However, the trajectory of the gain in CD4+T cells in patients receiving cART and whether, after several years, the rise in CD4+ T cells would tend to plateau are still unclear. Some studies correlated the rise to the baseline CD4+ T cell count; others found that time under treatment is most important.
From previous studies, it can be concluded that responses to cART are variable. The current study has the advantage of having one of the largest and most comprehensive databases available for evaluating the largest group of HIV-infected individuals over the longest period. Indeed, what this study has suggested is that all groups of persons begun on cART have a continuous rise in CD4+ T cells that asymptotically approaches normalization rather than reaching a plateau before normalization. What was not addressed was the functional capacity and durability of this CD4+ T cell response. While other data cannot rule out minor functional deficiencies in the capacity for the new CD4+ T cells to produce effective immunological responses to pathogens, most data have convincingly demonstrated that these new cells are highly effective in preventing the major opportunistic infections associated with HIV infection.
One intriguing note to the study was that persons who began cART only after the CD4+T cell count was G350 cells/μl had consistently lower CD4+ cells when compared with persons beginning cART when the CD4+T cell count was 9350 cells/μl, suggesting that early initiation of cART may be advantageous in ARV-naïve patients. It is unknown whether or not this differential would decrease if viral suppression can be maintained for longer periods of time. The question of when the most appropriate time is to initiate ART in the ART-naïve person is currently one of the most pressing issues in the care of HIV-infected individuals.
